Impact of Anorexia, Bulimia and Obesity on the Gynecologic Health of Adolescents

Dieting behaviors and nutrition can have an enormous impact on the gynecologic health of adolescents. Teenaged patients with

anorexia nervosa can have hypothalamic suppression and amenorrhea. In addition, these adolescents are at high risk of osteoporosis and fractures. Unfortunately, data suggest that estrogen replacement, even in combination with nutritional supplementation, does not appear to correct the loss of bone density in these patients. Approximately one half of adolescents with bulimia nervosa also have hypothalamic dysfunction and oligomenorrhea or irregular menses. Generally, these abnormalities do not impact bone density and can be regulated with interval dosing of progesterone or regular use of oral contraceptives. In contrast, the obese adolescent with menstrual irregularity frequently has anovulation and hyperandrogenism, commonly referred to as polycystic ovary syndrome. Insulin resistance is thought to play a role in the pathophysiology of this condition. While current management usually involves oral contraceptives, future treatment may include insulin-lowering medications, such as metformin, to improve symptoms. Because all of these patients are potentially sexually active, discussion about contraception is important. (Am Fam Physician 2001;64:445-50.)

Adolescence is a time of tremendous growth and development, in which nutrition plays a key role. The adolescent growth spurt accounts for approximately 25 percent of adult height and 50 percent of adult weight.1 Moreover, girls develop reproductive capacity during this time. Adolescents with disordered eating behaviors, such as anorexia nervosa, bulimia nervosa or obesity, frequently have menstrual abnormalities that reflect their abnormal nutritional intake. In this article, we will address these three common adolescent conditions and describe the pathophysiology and management of the abnormal menstrual patterns that accompany each.

Anorexia Nervosa

Once described by Hilde Bruch as the "relentless pursuit of thinness,"2 anorexia is a disorder that plagues approximately 0.5 to 1.0 percent of adolescents.3 The diagnostic criteria have evolved to those described in the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., and are summarized in Table 1.4 The intense fear of weight gain and the lack of self-esteem cannot be overstated and are factors that make this condition so painful for the young patient with anorexia. In addition, certain personality traits such as being perfectionistic, obsessive-compulsive, socially withdrawn, high-achieving (but rarely satisfied) and depressed are often noted in these patients. The patient with anorexia may exclusively restrict dietary intake (restrictive subtype) or may experience episodes of binging and purging (bulimic subtype).4

While the female adolescent with anorexia frequently experiences symptoms of anorexia such as weakness, dizziness or fatigue, she often seeks help (or is brought for medical attention by a distressed parent) because her weight loss has resulted in amenorrhea. The precise mechanism of amenorrhea in the patient with anorexia is not known. However, the severe caloric restriction suppresses the hypothalamic-pituitary axis.5 Biochemical mediators that have been implicated in this process include cortisol, leptin, growth hormone and insulin-like growth factor I6-9; all of these mediators play a role. The result is a dramatic suppression of the pituitary production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Without normal cycling of LH and FSH, the circulating level of estrogen is very low and ovulation will not occur. Fertility is therefore compromised in these patients.

The patient with anorexia also is at high risk of developing osteopenia and frank osteoporosis.10 Although the pathophysiology of osteoporosis is not well understood, it is known that adolescence is a critical time of bone mineralization. Estrogen appears to play a major role,11 although nutritional factors are also crucial.12 One study13 compared patients who had anorexia with those who had hypothalamic amenorrhea from other etiologies and found that those with anorexia had more profound osteopenia, supporting the theory that nutrition also plays an important role. Normalization of the patient's weight appears to be the single most important factor in regaining bone density.14 Even when this is achieved, bone may not remineralize to normal levels.

The key goals of managing patients with anorexia are overall improvement of body weight and normalization of eating patterns. For example, while oral contraceptives have successfully restored menses in such patients in clinical trials, they do not appear to substantially mitigate the osteoporosis. One study15 that examined women with amenorrhea from various causes suggested that prolonged treatment with oral contraceptives and calcium supplementation (duration of more than 12 months) may have a beneficial effect, but other studies16 do not support this finding.

In the adolescent with anorexia nervosa, normalization of body weight is the single most important factor in regaining bone density.

A recent, small study17 found that the use of oral dehydroepiandrosterone had a favorable effect on bone turnover in young women with anorexia; however, additional studies are necessary. Because some physicians use the return of menses to demonstrate regained health in the patient, they may not want to mask this outcome with the use of oral contraceptives. Therefore, evidence to date does not support the routine use of oral contraceptives in the management of patients with anorexia, but newer modalities may be on the horizon.

Osteoporosis is of concern not only later in life when the patient becomes postmenopausal but also during the adolescent years. The patient with anorexia characteristically exercises frequently and strenuously, and may be prone to stress fractures even after a short duration of the disorder. These patients must be informed about the risk of osteoporosis and fractures, and must be assessed with a bone mineral density study to ascertain their individual risk of pathologic fractures. In the female athlete, this is a particular concern. Eating disorders in these athletes are prevalent, and the triad of a menstrual disorder, an eating disorder and osteoporosis, or the "female athlete triad,"18 makes these patients quite vulnerable to fractures.

Bulimia Nervosa

Just as the diagnostic criteria for anorexia have been redefined over the years, so too have the criteria for bulimia. The current diagnostic criteria are detailed in Table 2.4 Whereas the prominent features of anorexia are the caloric restriction and resulting underweight, the prominent elements of bulimia are episodes of binge eating (large amounts of food with a lack of control) and the compensatory behaviors that follow, in a patient who is either normal weight or overweight. The compensatory behaviors include self-induced vomiting, abuse of laxatives and diuretics, over-exercise, caloric restriction and abuse of diet pills. Usually the patient suffers painful remorse after the behaviors but is unable to control the impulse to repeat them. The young woman with bulimia characteristically has low self-esteem, is depressed and/or anxious, and has poor impulse control. She typically engages in other risky behaviors, such as substance abuse, unprotected sexual activity, self-mutilation and suicide attempts.

While amenorrhea is a diagnostic criterion for anorexia, menstrual irregularity occurs in only about one half of patients with bulimia, probably because these women rarely achieve underweight when irregularity occurs. The mechanism appears to be related to hypothalamic-pituitary function. One study19 that examined body weight as a predictive factor of abnormal menstruation in patients with bulimia concluded that when current weight was less than 85 percent of a patient's past high weight, abnormal 24-hour secretion of LH is likely. This study followed another study20 that suggested decreased pulsatile LH secretion as a factor. Another very small study21 showed elevated levels of free testosterone in patients with bulimia.

The oligomenorrhea in patients with bulimia does not, however, appear to impact their bone mineral density. According to one study22 that compared patients with anorexia, patients with bulimia and matched control patients, bone mineral density in those patients with bulimia was similar to that in the control patients. Interestingly, this study also showed that weight-bearing exercise had a protective effect in patients with bulimia that did not occur in those with anorexia. Therefore, osteoporosis may not be a concern in patients with bulimia, particularly those who exercise regularly.

If menstrual irregularity occurs in the adolescent with bulimia, a limited evaluation is necessary. After completing a careful history and physical examination, the laboratory work-up depends on the particular pattern seen. If significant oligomenorrhea is reported, it may be helpful to obtain the patient's levels of LH and FSH, thyroid-stimulating hormone, prolactin, and total and free testosterone. If androgenization is present, obtaining a dehydroepiandrosterone sulfate level will help to evaluate adrenal function.  If a patient has not menstruated in three months or more, a progesterone challenge test (administration of medroxyprogesterone acetate [Provera] in a dosage of 10 mg daily for seven days) would be indicated. A withdrawal bleed two to seven days after treatment indicates sufficient levels of estrogen. In a chronically anovulatory teenaged patient who is not underweight and who has an elevated androgen level and positive results on the progesterone challenge test, one must assume that the patient has chronically circulating unopposed estrogen. In this situation, it is necessary to induce a withdrawal bleed at least every three months to reduce the risk of endometrial cancer later in life. This is done by repeating progesterone administration every three months or by cycling with combined oral contraceptive pills.

A few small studies have demonstrated that metformin (Glucophage) improves menstrual function and hyperandrogenism in patients with polycystic ovary syndrome.

Obesity

Obesity is a rapidly increasing, preventable cause of morbidity and mortality in the United States. Unfortunately, it frequently begins long before adulthood. Current estimates of the prevalence of obesity in youth as measured by the third National Health and Nutrition Examination Survey range from 11 to 24 percent.23 Estimates vary because measurement techniques, instruments and the actual definitions of overweight and obesity frequently differ from study to study. The importance of defining obesity and overweight is to determine when an adolescent is at risk of negative health consequences related to their weight. For example, while some researchers rely on the body mass index (BMI = weight in kilograms divided by height in meters squared),24 others use fat distribution, or waist-to-hip ratio.25-27

One large, prospective study28 demonstrated a direct correlation between increasing BMI (i.e., higher than 25) and increasing risk of premature death. If approximately one third of obese adolescents are predicted to be obese as adults,29 one may assume that the prevention or treatment of obesity can have a major impact on the future health of these patients.

Obesity may or may not impact the gynecologic health of an adolescent female. The effects of obesity are mediated primarily through hormonal changes. Insulin resistance is a well-established consequence of obesity.30,31 When it occurs, it can become so profound that it lowers glucose tolerance and precipitates type 2 diabetes mellitus (formerly known as non ­insulin-dependent diabetes mellitus), even during adolescence.

Insulin resistance also increases circulating levels of insulin, which elevate androgen production. A number of mechanisms for this have been found, including the lowering of sex-hormone ­binding globulin, increased androgen production by direct stimulation or indirectly by the production of insulin-like growth factor I. The relationship between insulin and androgens is thought to be the underlying trigger of polycystic ovary syndrome (PCOS), which is also known as functional ovarian hyperandrogenism.32 PCOS is a frequent cause of menstrual dysfunction in the adolescent.

PCOS is defined by elevated androgen associated with anovulation, which manifests clinically as oligomenorrhea and/or dysfunctional uterine bleeding. While it usually occurs in obese patients, it also may occur in patients with a normal weight. Hyperandrogenism can also lead to other undesirable effects such as hirsutism, acne, acanthosis nigricans and, less commonly, clitoromegaly. Because of the anovulation and the lack of progesterone production, a state of unopposed estrogen is induced. As mentioned earlier, this state increases the risk of endometrial cancer. Lowered fertility is also characteristic.

The diagnosis of PCOs is a clinical one; however, certain laboratory data, such as elevated androgen levels, can help to support the diagnosis. An elevated LH:FSH ratio may also be found but is not necessary for diagnosis. When evaluating the patient with suspected PCOS, it also is necessary to rule out other potential hormonal abnormalities such as thyroid disease, hyperprolactinemia or adrenal abnormalities. It is important to note, however, that ultrasonographic evidence of polycystic ovaries is not necessary for diagnosis and, in fact, polycystic ovaries may occur in normally menstruating patients.

Management of PCOS in the adolescent depends on each patient's clinical presentation. Most patients can be treated with combined oral contraceptives. This can reduce the potential worsening of the negative consequences of the syndrome, such as acanthosis nigricans, hirsutism, acne and glucose intolerance.33 This allows regular shedding of the endometrial lining of the uterus and lowers the patient's risk of endometrial cancer. If a patient is adverse to starting oral contraceptives, oral progesterone (Prometrium) may be used in a dosage of 10 mg daily for seven days, given every three months, to induce a withdrawal bleed. However, this will not alter the androgenic manifestations. In the young woman with severe hirsutism, spironolactone (Aldactone) in a dosage of 50 mg twice daily may be used as an effective alternative when the patient does not feel comfortable using oral contraceptives.

When the patient is overweight, a weight loss of at least 10 percent can improve the hormonal profile and the clinical manifestations of PCOS. Unfortunately, even with the best multidisciplinary programs, weight loss is difficult to achieve and even more difficult to maintain in many patients. Because insulin is thought to play a major role in the etiology of PCOS, researchers have begun to examine the regulation of insulin as a way to control PCOS. For example, a few recent, small studies have demonstrated that metformin (Glucophage) improves menstrual function and hyperandrogenism in patients with PCOS.34 Therefore, metformin or similar insulin-lowering medications may become the treatment of the future for PCOS.

Final Comment

An important note for the family physician caring for adolescent patients is the management of contraception in the patient who has an eating disorder or who is overweight. One must not assume, even in the morbidly obese patient, that an adolescent female is not sexually active. Therefore, it is essential to question all teenaged patients in a confidential, nonjudgmental manner about their sexual and gynecologic history and to assess their desire for contraception. Condoms alone or condoms plus spermicide are the options that have the fewest possible side effects. In the past, oral contraceptives have been associated with increased weight gain; however, the low-dose pills currently being used are much less likely to have this effect.35 In addition, for those adolescent patients who are identified as having PCOS, low-dose oral contraceptives will accomplish contraception while also lowering androgen levels. The hormonal contraception options that are more likely to cause weight gain are those with long-acting progestin, such as medroxyprogesterone acetate (Depo-Provera) and levonorgestrel (Norplant). These may be used as a last resort in patients whose need for contraception may override the potential harm from additional weight gain.

The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.

The Authors

MARJORIE KAPLAN SEIDENFELD, M.D., is an assistant clinical professor of pediatrics in the Division of Adolescent Medicine at the Mount Sinai School of Medicine of the City University of New York, N.Y. Dr. Kaplan received her medical degree from the Mount Sinai School of Medicine and completed a residency in pediatrics and a post-doctoral fellowship in adolescent medicine at Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, N.Y.

VAUGHN I. RICKERT, PSY.D., is director of research at the Mount Sinai Adolescent Health Center and associate professor in the Department of Pediatrics, Mount Sinai School of Medicine. He completed his doctoral degree in clinical psychology at Central Michigan University, Mt. Pleasant, and an internship at Johns Hopkins University School of Medicine, Baltimore, Md.

Address correspondence to Vaughn I. Rickert, Psy.D., Mount Sinai Adolescent Health Center, 320 E. 94th St., New York, NY 10128 (e-mail: vaughn.rickert@mountsinai.org). Reprints are not available from the authors.

REFERENCES

1. Shafer MB, Irwin CE. The adolescent patient. In: Rudolph AM, ed. Rudolph's Pediatrics. 19th ed. Norwalk, Conn.: Appleton & Lange, 1991:39.
2. Bruch H. Eating disorders: obesity, anorexia nervosa, and the person within. New York: Basic Books, 1973:294-5.
3. Hoek HW. The distribution of eating disorders. In: Brownell KD, Fairburn CG, eds. Eating disorders and obesity: a comprehensive handbook. New York: Guilford Press, 1995:207-11.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:541-50.
5. Golden NH, Jacobson MS, Schebendach J, Solanto MV, Hertz SM, Shenker IR. Resumption of menses in anorexia nervosa. Arch Pediatr Adolesc Med 1997;151:16-21.
6. Audi L, Mantzoros CS, Vidal-Puig A, Vargas D, Gussinye M, Carrascosa A. Leptin in relation to resumption of menses in women with anorexia nervosa. Mol Psychiatry 1998;3:544-7.
7. Nakai Y, Hamagaki S, Kato S, Seino Y, Takagi R, Kurimoto F. Leptin in women with eating disorders. Metabolism 1999;48:217-20.
8. Stoving RK, Hangaard J, Hansen-Nord M, Hagen C. A review of endocrine changes in anorexia nervosa. J Psychiatr Res 1999;33:139-52.
9. Nakai Y, Hamagaki S, Kato S, Seino Y, Takagi R, Kurimoto F. Role of leptin in women with eating disorders. Int J Eat Disord 1999;26:29-35.
10. Brooks ER, Ogden BW, Cavalier DS. Compromised bone density 11.4 years after diagnosis of anorexia nervosa. J Womens Health 1998;7:567-74.
11. Hergenroeder AC. Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 1995;126 (5 pt 1):683-9.
12. Rock CL, Gorenflo DW, Drewnowski A, Demitrack MA. Nutritional characteristics, eating pathology, and hormonal status in young women. Am J Clin Nutr 1996;64:566-71.
13. Grinspoon S, Miller K, Coyle C, Krempin J, Armstrong C, Pitts S, et al. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 1999;84:2049-55.
14. Goebel G, Schweiger U, Kruger R, Fichter MM. Predictors of bone mineral density in patients with eating disorders. Int J Eat Disord 1999;25:143-50.
15. Hergenroeder AC, Smith EO, Shypailo, R, Jones LA, Klish WJ, Ellis K. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol 1997;176:1017-25.
16. Mitchell JE, Pomeroy C, Adson DE. Managing medical complications. In: Garner DM, Garfinkel PE, eds. Handbook of treatment for eating disorders. 2d ed. New York: Guilford Press, 1997:389-90.
17. Gordon CM, Grace E, Emans SJ, Crawford MH, Leboff MS. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. J Bone Miner Res 1999;14:136-45.
18. Otis CL, Drinkwater B, Johnson M, Loucks A, Wilmore J. American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc 1997;29:i-ix.
19. Weltzin TE, Cameron J, Berga S, Kaye WH. Prediction of reproductive status in women with bulimia nervosa by past high weight. Am J Psychiatry 1994; 151:136-8.
20. Schweiger U, Pirke KM, Laessle RG, Fichter MM. Gonadotropin secretion in bulimia nervosa. J Clin Endocrinol Metab 1992;74:1122-7.
21. Sundblad C, Bergman L, Eriksson E. High levels of free testosterone in women with bulimia nervosa. Acta Psychiatr Scand 1994;90:397-8.
22. Sundgot-Borgen J, Bahr R, Falch JA, Schneider LS. Normal bone mass in bulimic women. J Clin Endocrinol Metab 1998;83:3144-9.
23. Troiano RP, Flegal KM. Overweight prevalence among youth in the United States: why so many different numbers? Int J Obes Relat Metab Disord 1999;23(suppl 2):S22-7.
24. Malina RM, Katzmarzyk PT. Validity of the body mass index as an indicator of the risk and presence of overweight in adolescents. Am J Clin Nutr 1999;70:S131-6.
25. Gillum RF. Distribution of waist-to-hip ratio, other indices of body fat distribution and obesity and associations with HDL cholesterol in children and young adults aged 4-19 years: The Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 1999;23:556-63.
26. Asayama K, Hayashi K, Hayashibe H, Uchida N, Nakane T, Kodera K, et al. Relationships between an index of body fat distribution (based on waist and hip circumferences) and stature, and biochemical complications in obese children. Int J Obes Relat Metab Disord 1998;22:1209-16.
27. Daniels SR, Morrison JA, Sprecher DL, Khoury P, Kimball TR. Association of body fat distribution and cardiovascular risk factors in children and adolescents. Circulation 1999;99:541-5.
28. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341:1097-105.
29. Guo SS, Chumlea WC. Tracking of body mass index in children in relation to overweight in adulthood. Am J Clin Nutr 1999;70:S145-8.
30. Ravussin E, Gautier JF. Metabolic predictors of weight gain. Int J Obes Relat Metab Disord 1999; 23(suppl 1):37-41.
31. Sinaiko AR, Donahue RP, Jacobs DR, Prineas RJ. Relation of weight and rate of increase in weight during childhood and adolescence to body size, blood pressure, fasting insulin, and lipids in young adults. The Minneapolis Children's Blood Pressure Study. Circulation 1999;99:1471-6.
32. Acien P, Quereda F, Matallin P, Villarroya E, Lopez-Fernandez JA, Acien M, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999;72:32-40.
33. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol 1999;50:517-27.
34. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85:139-46.
35. Reubinoff BE, Grubstein A, Meirow D, Berry E, Schenker JG, Brzezinski A. Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril 1995;63:516-21.

next: Why Do Women Feel OK About Their Bodies Until Other Women Show Up?
~ eating disorders library
~ all articles on eating disorders